Q-omics provides the consensus-scored EPHA10 profile across patient tissues and cancer cell-line models. EPHA10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, EPHA10 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, EPHA10 RNA expression shows 15,432 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UCEC, THCA, and ESCA as cancer lineages where EPHA10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPHA10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPHA10 survival associations across molecular data types. EPHA10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPHA10 RNA expression–survival associations across cancer types. High EPHA10 expression shows unfavorable associations in UCEC and KIRC, but favorable associations in HNSC, LGG, BLCA and READ. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for EPHA10 RNA expression.
This table summarizes EPHA10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for EPHA10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPHA10 shows lower tumor expression in COAD and higher tumor expression in THCA, LUAD, STAD, BRCA and LIHC. The THCA box plot shows higher EPHA10 RNA expression in tumor versus normal tissue (log2 FC = +2.735, t-test p < 0.001).
This table shows molecular features associated with EPHA10 in patient tissues and cancer cell lines. In patient samples, EPHA10 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, EPHA10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
